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Immunological functions of mast cells are currently considered to be much broader than the original role of
mast cells in IgE-driven allergic disease. The spectrum of proposed mast cell functions includes areas as
diverse as the regulation of innate and adaptive immune responses, protective immunity against viral, micro-
bial, and parasitic pathogens, autoimmunity, tolerance to graft rejection, promotion of or protection from
cancer, wound healing, angiogenesis, cardiovascular diseases, diabetes, obesity, and others. The vast
majority of in vivo mast cell data have been based on mast cell-deficient Kit mutant mice. However, work
in new mouse mutants with unperturbed Kit function, which have a surprisingly normal immune system,
has failed to corroborate some key immunological aspects, formerly attributed to mast cells. Here, we
consider the implications of these recent developments for the state of the field as well as for future work,
aiming at deciphering the physiological functions of mast cells.Introduction
The original recognition of immunological hyperreactivity and
allergic inflammation dates back more than 100 years. Paul
Ehrlich, referring to self-reactive antibodies, coined the term
‘‘horror auto-toxicus’’ (the fear of being toxic to oneself) but
rejected the idea that immunological autoaggression would
exist or make sense (Ehrlich, 1901). Clemens von Pirquet
conceived the concept of allergy as immunological hyperreac-
tivity (von Pirquet, 1906). The mast cell, discovered (Ehrlich,
1877) well before allergy was recognized as a regular inducible
immunological phenomenon, happens to be at the center of
anaphylaxis and allergic inflammation (Mota and Vugman,
1956), with IgE (Ishizaka and Ishizaka, 1966) providing the link
between antigen (allergen) and the high-affinity IgE receptor
(FcεRI) (Blank et al., 1989) expressed on mast cells. Mast cells
can be viewed as the immune system’s loaded gun. There is
arguably no second cell type in the immune system as powerfully
equipped with a large array of chemically diverse and highly
potent compounds. Mast cell products cover a wide range of
biological activities from the promotion of local inflammation to
the regulation of systemic blood pressure and vessel perme-
ability. Upon stimulation, mast cells rapidly release by degranu-
lation, among other products, histamine, heparin and other
proteoglycans, granule-associated proteases, and they produce
leukotriens and prostaglandins. Mast cell products can kill hu-
mans and animals within minutes in what is known as anaphy-
laxis (Portier and Richet, 1902). In addition, mast cells also
produce chemokines and cytokines (reviewed in Galli et al.,
2008), notably IL-4 and IL-13, key factors initiating or augment-
ing type 2 immunity (Liang et al., 2012).
To this date, the ‘‘positive’’ counterpart to the mast cell’s
‘‘negative’’ role in the allergic arm of immunity remains puzzling.
Although exposure to and protective immunity against patho-
gens has been found inversely correlated with the emergence
of allergic disease (Ege et al., 2011), the phenomenon of
allergy per se, i.e., hyperreactivity upon repeated encounterwith innocuous substances, remains a paradox of the immune
system. As with other weapons, the terms of usage (i.e., licensed
or not) and the targets (e.g., self-tissues or pathogens) determine
harm (as in allergy) or protection (as in resolving and lasting
immunity). The notion of a primary function of mast cells in the
promotion of allergic inflammation is difficult to accept. Yet,
exactly this undesired and in extreme cases devastating role of
mast cells in allergic disease remains the best-understood and
-documented function. The essential role of mast cells in this
type of immune reaction is underscored by the fact that mast
cell-deficient mice are unable to mount IgE-mediated local and
systemic anaphylaxis (Feyerabend et al., 2011; Lilla et al.,
2011; Sawaguchi et al., 2012; Wershil et al., 1987). In KitW/Wv
(Wershil et al., 1987) and in Cpa3Cre (Feyerabend et al., 2011)
mice, the defect in the response was restored upon mast cell
transfers.
For a long time, this culprit role of mast cells in allergic disease,
and the concomitant lack of known functions in protective
immunity, hindered mast cells from entering immunology’s
center stage. This situation has changed dramatically over the
past years, as manifold functions for mast cells have been re-
ported. Roles for mast cells have been reported in the regulation
of innate and adaptive immune responses, including tolerance
to skin graft rejection (de Vries and Noelle, 2010; Lu et al.,
2006), in settings of T cell and antibody mediated autoimmunity
(Sayed et al., 2008), in protective immunity against viral (Wang
et al., 2012) andmicrobial (Chan et al., 2012) pathogens, in tissue
remodeling, wound healing (Gilfillan and Beaven, 2011) and
angiogenesis (Coussens et al., 1999), in cancer promotion or
protection from cancer by participation in tumor stroma (Tlsty
and Coussens, 2006), and in immune-metabolic syndromes of
diabetes and obesity (Liu et al., 2009). Beyond these immune
functions, mast cells have been proposed to be involved in
diverse areas including vascular diseases (Bot and Biessen,
2011), anxiety behavior (Nautiyal et al., 2008), male (Haidl
et al., 2011) and female (Menzies et al., 2011) fertility, andImmunity 37, July 27, 2012 ª2012 Elsevier Inc. 13
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evident from this all but complete list that, if indeed true, mast
cells have a huge spectrum of functions. Outside observers
might not be the only ones concerned that this list could be an
‘‘immunological bubble.’’ If not, mast cells were indeed among
the cells with the most pleiotropic functions in the immune
system, and beyond. It is interesting to note that many authors
of primary and reviewing literature emphasize the versatility of
mast cell functions, meaning that mast cells’ behavior, e.g., as
suppressers or enhancers of inflammation, may vary depending
on the context. It is often ambiguous whether ‘‘context’’ refers
to experimental conditions or to physiological or pathological
states. Althouh this idea may appropriately describe mast cell
functions, it can also accommodate conflicting data, and
a degree of vagueness remains inherent to this concept. Many
of the reported mast cell functions listed above have remained
controversial or, at least, have not been independently verified
in different experimental settings, such as in independent mouse
models. In conclusion, mast cells and the mast cell enigma
have kept their fascination, and, in our view, many physiological
functions of mast cells beyond allergic disease remain to be
unequivocally demonstrated.
In this article, we refrain from an in-depth review of the most
prominent and recent mast cell literature along the lines of the
listed functions stated above. Instead, our goal is to provide
a framework in which to consider past and discuss future ex-
perimental settings and their implications to test relevant mast
cell functions under physiological and pathological conditions.
With this in mind, key topics to be covered are, in brief, the
role of Kit in mast cell research, the use of cultured mast cells
as in vivo tools, and the quest for Kit-independent mast cell
deficiency models, followed by a brief overview of proven and
more speculative roles of mast cell functions. We have no
answer to the title of this review yet, but we hope to stimulate
discussions and, most of all, new experiments that may eventu-
ally provide the answer in the future.
The Receptor Tyrosine Kinase Kit and Mast Cells:
A Close Liaison in Its 35th Year
Mast cells are strictly tissue-localized cells, and under normal
healthy conditions, they are undetectable in bone marrow
and peripheral blood. Bone marrow transplantation (Kitamura
et al., 1977) and mast cell progenitor identification (Rodewald
et al., 1996) established that mast cells belong developmentally
to the hematopoietic lineage. The mutation underlying the
phenotype of dominant white spotting (W) mouse strains
(Russell, 1979) was linked to mast cells by showing that W
mouse mutants are mast cell-deficient (Kitamura et al., 1978).
The reconstitution of donor mast cells in recipient W mice by
wild-type bone marrow transplantation marked the beginning
of the era in which W mice served as in vivo models to inves-
tigate mast cell functions. White spotted mice exist in variable
phenotypic penetrations, depending on the different naturally
occurring alleles, termed KitW, KitWv, and KitW-sh (Nocka
et al., 1990), to name those most relevant for the mast cell
field. The receptor tyrosine kinase Kit maps to the mouse
W locus, and Kit mutations are causal for the phenotypes of
W mice, including their mast cell deficiency. Kit ligand (Kitl) is
a microenvironmental stromal cell factor encoded at the Steel14 Immunity 37, July 27, 2012 ª2012 Elsevier Inc.(Sl) locus. Sl mutants also lack mast cells (Galli and Kitamura,
1987).
The vast majority of the existing in vivo mast cell literature is
based on the viable compound mutant KitW/Wv mouse. The KitW
allele-encoded protein cannot be expressed on the cell surface,
while the kinase activity is impaired in the KitWv-encoded protein
(Nocka et al., 1990). KitW/Wv mice are severely affected by their
Kit deficiency in several tissues. In the context of the long-
standing use of these mutants as mast cell deficiency models,
it is worth to consider some key aspects of Kit biology. Kit is
expressed inside and outside of the hematopoietic system in
cell types of diverse developmental origin. Within the immune
system, Kit is an important hematopoietic stem and progenitor
cell marker, which is expressed in these cell types at high levels.
In most lineages, Kit expression is lost with differentiation. The
notable exception are mast cells in which Kit expression remains
very strong throughout their development. Kitl is a key growth
factor for mast cells in vivo. The block in mast cell development
in Kitmutant mice is, however, not absolute. In vitro, interleukin-
3 (IL-3) can drive the development of bone marrow-derived mast
cell cultures (BMMCs) from Kit mutant bone marrow cells. In
contrast to the strict requirement for Kit signaling in mast cells
in vivo, IL-3 is sufficient and the most potent mast cell growth
factor in vitro (Nabel et al., 1981; Yokota et al., 1984; Yung
and Moore, 1982), where Kitl synergizes with IL-3 for optimal
mast cell growth. Surprisingly, steady state mast cell develop-
ment was normal in Il3-deficient mice (Lantz et al., 1998), under-
scoring fundamentally different growth requirements in vivo and
in vitro. The mast cell deficiency of KitW/Wv mice can be partially
overcome by chronic inflammatory stimuli in vivo (Gordon and
Galli, 1990; Waskow et al., 2007), which may limit the use of
these mice under certain conditions of chronic inflammation.
In addition to their mast cell defect, KitW/Wvmice have multiple
hematopoietic abnormalities that include compromised fitness
of hematopoietic stem and progenitor cells (Russell, 1979),
severe macrocytic anemia (Waskow et al., 2004), impaired
T development in the thymus (Waskow et al., 2002), a shift in
intraepithelial T cells in the gut in favor of TCR ab+ and against
TCR gd+ cells (Puddington et al., 1994). Importantly, this Kit
mutant is neutropenic, which may be a major factor affecting
immune responses in this strain (Zhou et al., 2007).
It has been reiterated (Galli and Kitamura, 1987; Grimbaldes-
ton et al., 2005) that numbers of basophils are not affected in
KitW/Wvmice. This claim appears to rest on an older study based
on the morphological identification of basophils in peripheral
blood (Jacoby et al., 1984). Morphology and cell surfacemarkers
of mouse basophils have been controversial (Lee and McGarry,
2007). Based on flow cytometric phenotype, cytokine (IL-4)
production, and other functions, the current consensus on
mouse basophils is that these cells can be identified by their
DX5+Kit-FcεRI+ phenotype (Karasuyama et al., 2011; Siracusa
et al., 2011 and references therein). Using this definition, two
recent reports found 75%–90% reduced basophil numbers in
the peripheral blood (Mancardi et al., 2011) and spleen (Feyera-
bend et al., 2011) of KitW/Wvmice. This paucity of basophils may
be a contributing factor in phenotypes of KitW/Wv mice that have
been attributed to the lack of mast cells.
More recent publications have often used KitW-sh/W-shmice for
mast cell studies because these mice have fewer defects
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contrast to KitW/Wv mice, KitW-sh/W-sh mice are fertile and have
normal red blood cell numbers. Initially, KitW/Wv/KitW-sh/W-sh
mice were thought to have normal levels of all major classes of
hematopoietic cells including leukocytes (Grimbaldeston et al.,
2005 and references therein). However, a study found neutro-
philia, megakaryocytosis, and thrombocytosis in KitW-sh/W-sh
mice, whichwere associated with splenomegaly and histological
aberrations of the spleen (Nigrovic et al., 2008). The KitW-sh
allele is characterized by a large genomic inversion on chro-
mosome 5, the 30 end of which is located 75 kb upstream
of the Kit locus (Berrozpe et al., 1999; Nigrovic et al., 2008).
This genomic rearrangement does not only deregulate the
temporal and tissue-specific expression of Kit itself, which can
explain the mast cell deficiency (Berrozpe et al., 2006), but also
potentially leads to the disruption or deregulation of the 27 genes
located in the inverted genomic region, including disruption of
Corin, which causes cardiac hypertrophy (Nigrovic et al., 2008).
In summary, Kit is an essential receptor driving mast cell devel-
opment in vivo, and mice carrying inactivating mutations in Kit
have remained the main models in studies of mast cell functions.
However, in addition to their mast cell deficiency, Kit mutants
suffer from further defects in the hematopoietic system.
Roles of Kit Outside of the Immune System
Kit functions are important in germ cells and melanocytes (Be-
smer et al., 1993), intestinal pacemaker cells (Sergeant et al.,
2002), neuronal cells (Milenkovic et al., 2007), and liver metabo-
lism (Magnol et al., 2007). Kit-related phenotypes in these tissues
may indirectly perturb immunological experiments locally or
systemically, e.g., an altered threshold of nociception may influ-
ence inflammatory responses. Roles of mast cells have often
been studied in organs that are intrinsically affected by Kitmuta-
tions. In Kit mutant mice, intestinal pacemaker cells of Cajal fail
to develop, which results in insufficient intestinal peristaltic
movement (Huizinga et al., 1995; Maeda et al., 1992), gut dilata-
tion, and delayed intestinal passage times (Snoek et al., 2011).
These pathophysiological parameters can influence the compo-
sition of intestinal microbiota, or intestinal pathology. KitW/Wv
mice aremore susceptible to enterobacterial sepsis in the caecal
ligation and puncture (CLP) model (Echtenacher et al., 1996).
This higher vulnerability of KitW/Wv mice has been explained by
their mast cell deficiency, leading to insufficient production of
protective TNF-a. However, the situation in the CLP model is
complex because TNF-a has also been implicated in a worse
outcome in a severe version of the model (Piliponsky et al.,
2010). In addition, an involvement of the Kit mutations in CLP
experiments in KitW/Wv mice cannot be excluded because the
cecum, which is the target organ in this model, is highly dilated
in KitW/Wv mice, and this intestinal phenotype on its own may
impair resolution of the puncture. Collectively, the involvement
of Kit signaling in the development or function of cells outside
of the immune systemmay have an impact onmast cell research
in Kit mutants.
Mast Cell Reconstitution of Kit Mutant Mice: A Gold
Standard Less Golden?
It is obvious that the multitude of non-mast cell-related defi-
ciencies in Kit mutants may influence the outcome of experi-ments addressing in vivo mast cell functions. Bone marrow
transplantation can reconstitute wild-type hematopoietic cells
in KitW/Wv mice, and it cures their mast cell deficiency and, for
example, their anemia, but their mast cell defect is not selectively
corrected. In contrast, reconstitution ofKitmutant mice only with
BMMCs without hematopoietic stem cells appeared to offer
a solution for this problem (Nakano et al., 1985; Tsai et al.,
2005). The rational appears compelling: If mast cell-reconsti-
tuted Kit mutant mice show a reversal of the presumed mast
cell-dependent phenotype, e.g., if wild-type mice are resistant
to sepsis, KitW/Wv mice are susceptible, and mast cell-repleted
KitW/Wv mice are resistant, the conclusion seemed warranted
that the mast cell deficiency of KitW/Wvmice was the responsible
cellular defect underlying susceptibility (Echtenacher et al.,
1996). Effectively, the mast cell reconstitution system has
been, by and large, the mainstay to test mast cell functions
in vivo, and this approach has been considered a pillar of immu-
nology (Kawakami, 2009).
Does mast cell reconstitution lead to physiological mast cell
populations? Although BMMCs can adopt the phenotype of
normal tissue mast cells after in vivo transfer (Nakano et al.,
1985), numbers, distribution, and functional responses of
reconstituted mast cells may not be physiological (Ebmeyer
et al., 2010; Grimbaldeston et al., 2005; Nakano et al., 1985).
The distribution is a worthwhile consideration because mast cell
numbers may not only be lower than normal in one tissue but
also higher than normal in another. The route of transfer (local
versus systemic) matters, and the reconstitution can vary
between individual mice. Mast cell reconstitution has regularly
been demonstrated histologically, e.g., acquisition of a con-
nective tissue mast cell phenotype by safranin staining, but it is
difficult to go further and prove that engrafted mast cells behave
immunologically like normal endogenously developedmast cells.
Recent experiments have uncovered that BMMC reconstitu-
tion can erroneously lead to the reversal of a phenotype in Kit
mutants. Disturbingly, experiments comparing conventional
Kit mutant mast cell-deficient mice and mast cell reconstituted
Kit mutant mice versus selectively mast cell-deficient mice
wild-type for Kit (Dudeck et al., 2011; Feyerabend et al., 2011,
discussed in Katz and Austen, 2011) led to fundamentally
different results. Roers and colleagues studied contact hyper-
sensitivity in the skin. These authors found thatmast cell-specific
deletion of Il10 inMcpt5-Cre mice, a Cre transgene that deletes
LoxP-site flanked gene segments in connective tissue mast
cells, failed to reveal a role for mast cell-derived IL-10 in the regu-
lation of contact hypersensitivity (Dudeck et al., 2011). Earlier
studies using the mast cell reconstitution approach by transfer
of Il10-deficient BMMCs into Kit mutants concluded that mast
cell-derived IL-10 is important (Grimbaldeston et al., 2007).
Further conflicting results comparing Kit mutant mast cell-defi-
cient and Kit-independent mast cell-deficient mice were found
in experiments on the roles of mast cells in autoimmunity (dis-
cussed in Brown et al., 2012; Rodewald, 2012). On the basis of
work in KitW/Wv mice, key roles for mast cells had been reported
in the K/BxN autoantibody-driven arthritis models (Lee et al.,
2002) and in myelin oligodendrocyte glycoprotein (MOG)35–55
peptide immunization-driven experimental autoimmune en-
cephalomyelitis (EAE) (Secor et al., 2000, reviewed in Benoist
and Mathis, 2002; Sayed et al., 2008). In both cases, the mastImmunity 37, July 27, 2012 ª2012 Elsevier Inc. 15
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mice with BMMCs. Surprisingly, Kit-independent mast cell-
deficient Cpa3Cre/+ mice were fully susceptible to the K/BxN
arthritis and to EAE (Feyerabend et al., 2011). In these studies,
KitW/Wv mice were included in the experiments as controls. For
the K/BxN arthritis, the susceptibility of KitW/Wv mice was
confirmed, but notably not for EAE (Feyerabend et al., 2011).
Questions about the importance of mast cells in arthritis had
been raised earlier. Whereas KitW/Wv mice were not only pro-
tected in the K/BxN model but also in anti-collagen antibody-
induced arthritis, KitW-sh/W-sh mice were susceptible in both
models (Mancardi et al., 2011; Zhou et al., 2007).
Inevitably, these examples strongly suggest that Kit muta-
tions can contribute to the phenotype of mast cell experiments,
and that mast cell-reconstituted Kit mutants can behave
differently from normal mice with and without mast cells, a
divergence that remains to be understood. These examples of
fundamental discrepancies between Kit mutant mast cell-
deficient mice and mast cell-deficient mice wild-type for Kit
may remain the exception. We believe, however, that the robust-
ness of the Kit-based system, including mast cell reconstitution,
is doubtful as soon as a single example has been found in which
the system did not report with fidelity on in vivo mast cells
functions. Although cumbersome and possibly of little reward,
it may be prudent to readdress key mast cell findings based
on Kit mutant mice also in Kit-independent models.
Kit-Independent Mast Cell-Deficient Mice: Problems,
Solutions, and Limitations
The quest to develop Kit-independent mast cell-deficient mice
was aided by advances in gene targeting and transgenesis.
The identification of genes expressed specifically in mast cells
helped to identify ‘‘driver loci’’ that are instrumental for genetic
manipulation of mast cells in vivo. Some years ago, several
groups reported the generation of mice expressing Cre recom-
binase under the control of mast cell protease genes (Feyera-
bend et al., 2009; Mu¨sch et al., 2008; Scholten et al., 2008),
and in 2011, four laboratories used their mice or additionally
generated lines to obtain Kit-independent mast cell-deficient
mouse strains (Dudeck et al., 2011; Feyerabend et al., 2011; Lilla
et al., 2011; Otsuka et al., 2011). The strains differ in the selected
gene loci, the methods to drive ectopic gene expression in mast
cells (targeted knock-in or transgenic overexpression), and the
depletion mechanisms. In brief, Dudeck et al. (2011) and Otsuka
et al. (2011) used the diphtheria toxin (DT) system for depletion of
the mast cell lineage, Feyerabend et al. (2011) ablated mast cells
constitutively by exploiting the genotoxicity of Cre-recombinase,
and Lilla et al. (2011) depleted mast cells by Cre-mediated dele-
tion of an apoptosis suppressor gene. Strain-specific character-
istics are summarized in Table 1.
Dudeck et al. (2011) expressed Cre recombinase from the
first exon of mouse mast cell protease 5 (Mcpt5) in a bacterial
artificial chromosome (BAC) transgene harboring the Mcpt5
locus (Scholten et al., 2008) and used Mcpt5-Cre to activate
a Cre-dependent expression cassette in the ROSA26 locus of
the mast cell lineage. Two different versions of mice have been
presented. Depending on the ROSA26 allele, expression of the
catalytically active diphtheria toxin A subunit (R-DTA) or of the
human diphtheria toxin receptor (iDTR) was induced. Therefore,16 Immunity 37, July 27, 2012 ª2012 Elsevier Inc.Mcpt5-Cre x R-DTAmice represent a model of constitutive mast
cell deficiency, while inMcpt5-Cre x iDTRmicemast cell ablation
can be induced by repetitive diphtheria toxin injections. Given
that expression of the Mcpt5 transgene is restricted to connec-
tive tissuemast cells (CTMCs), CTMCs can be targeted, whereas
mucosal mast cell (MMC) compartments remain unaffected.
Deletion was most complete in peritoneal mast cells. Remaining
numbers of skin mast cells varied from 3.5% (ear skin) to 11%
(abdominal and back skin) in R-DTA mice. In iDTR mice, mast
cells were reduced to 2.5% (ear skin) after DT injections. Long-
term experiments inMcpt5-Cre x iDTRmice required continuous
DT injections because, within 3 weeks after the last DT injection,
10% of normal mast cell numbers reappeared. A major advan-
tage of the Mcpt5-Cre mice is that these mice can also be used
to delete floxed genes in CTMCs (Dudeck et al., 2011) and that
numbers of basophils are, at least in the bone marrow, not
impaired. Possible disadvantages are potential side effects of
toxin applications (Lahl and Sparwasser, 2011), the mast cell
rebound after ablation, which complicates long-term experi-
ments, and the exclusion of MMCs.
The mast cell-deficient mouse reported by Otsuka et al. (2011)
and Sawaguchi et al. (2012) is an inducible model based on
DTR expression. In mast cell-specific enhancer-mediated toxin
receptor-mediated conditional cell knockout (Mas-TRECK)
mice, DTR expression is driven as a transgene by an Il4 intronic
enhancer element that normally drives IL-4 expression in mast
cells. As in the case of Mcpt5-Cre x iDTR mice, repetitive toxin
injections are required for mast cell depletion. The authors
achieved full depletion of mast cell compartments in peritoneal
cavity, ear, and back skin, stomach, and mesentery, which
included CTMCs and MMCs. It remains to be tested whether
under certain inflammatory conditions mast cells can overcome
the depleting effect of DT. Of note, Mas-TRECK mice are fully
deficient for both mast cells and basophils. As a result, Mas-
TRECK mice are fully protected (Otsuka et al., 2011; Sawaguchi
et al., 2012) from mast cell-dependent IgE-mediated local and
systemic anaphylactic responses aswell as basophil-dependent
IgE-mediated chronic allergic inflammation (Karasuyama et al.,
2011). An additional mouse strain selectively lacking basophils
but not mast cells has been generated by a similar strategy
(Bas-TRECK) (Otsuka et al., 2011; Sawaguchi et al., 2012), and
the authors propose to analyze mast cell functions by compar-
ison of Mas-TRECK and Bas-TRECK mice, or to make use of
a ‘‘window,’’ in which basophils, but not mast cells, have
rebound from the bone marrow after depletion.
Cre recombinase is widely used to delete and recombine DNA
fragments within the mouse genome between introduced loxP
sites, but Cre can also be toxic independent of loxP target sites
when its expression is very strong or long lasting (Schmidt-
Supprian and Rajewsky, 2007). In the mast cell-deficient mouse
made by Feyerabend et al. (Cpa3Cre/+), the genotoxic effect of
Cre constitutively deleted the entire mast cell lineage. An ex-
pression construct, containing a codon-improved cDNA of Cre
(iCre), preceded by an untranslated exon and an intron for RNA
stability (references in Feyerabend et al., 2011), was introduced
into the first exon of the Cpa3 locus by homologous recom-
bination in embryonic stem cells. TheCpa3 locus is very strongly
expressed in mast cells, as highlighted in a reporter knockin
mouse (unpublished data). Cre expression from the Cpa3
Table 1. Overview of Kit-Independent Mast Cell Deficiency Mouse Models
Mcpt5-Cre Mas-TRECK Cre-Master Cpa3-Cre
Official Nomenclature Tg(Cma1-cre) ARoer Cpa3tm3(icre)Hrr Tg(Cpa3-cre)3Glli
Reference Dudeck et al., 2011 Otsuka et al., 2011;
Sawaguchi et al., 2012
Feyerabend
et al., 2011
Lilla et al., 2011
Mast Cell Specificity Mcpt5 BAC transgene (67 kb 50
and 46 kb 30)
IL4 intronic enhancer
(4.5 kb) plus IL4
promoter (0.76 kb)
transgene
targeted knockin
into the
endogenous
Cpa3 locus
Cpa3 promoter
(0.78 kb)
transgene
Induced or Depleted
Additional Loci
R-DTA iDTR not required not required Mcl-1fl/fl
Depletion Mechanism constitutive:
Cre-mediated
induction of DTA
expression from
the ROSA26 locus
inducible:
Cre-mediated
induction of the
DT-receptor +
repetitive
DT injections
inducible: DTR
expression +
repetitive
DT injections
constitutive:
Cre-mediated
genotoxicity
constitutive:
conditional
knockout of the
intracellular
anti-apoptotic
factor Mcl-1
Mast Cell Depletion up to 97% of CTMCs, depending
on the DT injection protocol; MMCs
are not depleted
deficient for
CTMCs and MMCs
(steady state)
deficient for CTMCs
and MMCs (steady
state and upon
inflammation)
92%–100%
including
CTMCs and
MMCs
Basophils not affected entirely depleted reduced to 38% reduced to 22%–42%
Significant Alterations
in Other Blood Cells
not detected not detected not detected macrocytic anemia,
neutrophilia
IgE-Mediated
Anaphylactic Response
not analyzed absent absent reduced
MC Recurrence steady state: MCs back to 10% at
1–3 weeks after last DT injection
steady state:
MC deficiency
lasts >18 days
after last DT
injection; blood
basophil numbers
are normal again
by day 12
steady state:
no
inflammation
or parasite
infections: no
not analyzed
This table summarizes genetic and functional properties of recently developed Kit-independent mast cell deficiency models. Official nomenclature
refers to the entry at the Mouse Genome Informatics (MGI) Database, The Jackson Laboratories.
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to chromosomal lesions brought about by Cre action on endog-
enous pseudo-loxP sites in the mouse genome (discussed in
Feyerabend et al., 2011). Cre-mediated mast cell eradication
(Cre-Master; Cpa3Cre/+) mice were entirely mast cell-deficient
for both CTMCs and MMCs in peritoneal cavity, ear skin, and
intestinal mucosa, and they were protected from passive local
or systemic anaphylaxis. Chronic inflammatory conditions did
not overcome the mast cell deficiency. This holds true for
CTMCs, as demonstrated in PMA-induced dermatitis, and for
MMCs in the intestine upon nematode infections. Detailed
analyses of hematopoietic cell subsets and blood parameters
revealed a normal steady-state immune system in Cre-Master
mice. Even though Cpa3 expression is not absolutely restricted
to the mast cell lineage, expression levels in other lineages are
tooweak to render Cre recombinase toxic, except for a reduction
of basophils to 40% of wild-type mice. Further work will be
required to analyze whether the residual basophils are function-
ally impaired due to Cre expression in this lineage.
Lilla et al. developed a Cpa3-Cre transgenic mouse strain,
carrying a 780 bp region of the Cpa3 promoter in front of theCre recombinase cDNA. This mouse was crossed to mice with
floxed myeloid cell leukemia sequence 1 (Mcl1) alleles to specif-
ically delete the Mcl1 gene in mast cells. Mcl1 is an intracellular
antiapoptotic factor and conditional deletion of its gene in Lck-
Cre or CD19-Cre mice has previously been shown to induce
depletion of T and B cell lineages. Lilla et al. analyzed a compre-
hensive set of organs, including connective andmucosal tissues,
for the presence or absence of mast cells, and reported 92%–
100% mast cell depletion. The relatively largest residual mast
cell numbers were found in back skin and the peritoneal cavity.
In addition, basophil numbers were reduced by 58%–78% in
spleen and bone marrow, respectively. These mice also showed
a 56% increase in splenic neutrophils and macrocytic anemia.
The reasons for these hematological abnormalities are unclear,
but it is possible that Cpa3 expression outside of the mast cell
lineage, e.g., in other myeloid progenitors and in the majority of
progenitor T cells (Feyerabend et al., 2009), contributes to
some of these alterations. In any case, it is unlikely that these
defects are related to the mast cell deficiency because other
mice selectively lacking mast cells did not show deviations in
neutrophils or erythrocytes.Immunity 37, July 27, 2012 ª2012 Elsevier Inc. 17
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research. These mice shall directly allow assessments on the
roles of mast cells independent of Kit defects. By comparison
to Kit mutants, they will also shed light on the roles that
Kit played in particular physiological or pathological questions
that were studied in the context of mast cell functions. Further
advantages of these strains are their ease of breeding, which
will facilitate the generation of mast cell-deficient mice on
immunologically interesting genetic backgrounds, which criti-
cally effect immunological responsiveness, like T helper cell
skewing and tissue transplantation, to name a few. Likewise, it
will be easier to study the role of mast cells in complex immuno-
logical diseases like diabetes (NOD) and rheumatoid arthritis, or
to combine mast cell deficiency with transgenic models. Finally,
the possibility to conditionally delete genes in mast cells will be
crucial for rigorous evaluation of specific gene functions
in mast cells.
Does Mast Cell Deficiency Exist in Humans?
Genetic analysis of human patients is an important tool for the
discovery of cellular and molecular mechanisms underlying
immunity and for the identification of mutations associated
with clinical disease. To our knowledge, humans lacking mast
cells have not been reported. A possible but far-fetched explana-
tion could be lethality prior to birth caused by lack of mast cells.
Alternatively, lack of mast cells does not cause immunodefi-
ciency or immune deviation, in which case individuals are
clinically inconspicuous. If mast cell deficiency in humans, as
in mice, were neither lethal nor disease-causing, individuals
lacking mast cells might be ‘‘hidden’’ in the nonallergic popula-
tion. It shall be important to gain insights into the ‘‘positive’’
immunological roles of mast cells also in humans before global
interference with mast cells or their functions can be considered
a therapeutic goal in the treatment or prevention of allergic
disease. In selectively mast cell-deficient mice, steady state
immune parameters (numbers and proportions of large sets of
lymphocyte and myeloid subpopulations; serum Ig titers; hema-
topoietic stem and progenitors in bone marrow; T helper cell-2-
dependent IgG1 antibody response including class switching
and somatic hypermutation) were all unaffected by the lack of
mast cells (Feyerabend et al., 2011). A teleological argument,
that mast cells must be important because they exist, is not
helpful in deciphering the biological functions of mast cells.
The hurdle in screening for those myeloid cell types that cannot
readily be identified automatically in peripheral blood, and the
unexpectedly restricted spectrum of immunodeficiency in hu-
mans devoid of dendritic cells has recently been discussed
(Collin et al., 2011). Although analogous data for mast cells are
lacking, similar considerations for the identification of mast cell
deficiency should apply. In brief, while human mast cell defi-
ciencymight have tremendous implications for mast cell biology,
the search for such individuals remains complex.
Experimental Basis for Assumed Mast Cell Functions
in the Immune System
A critical assessment of immunological and nonimmunological
roles of mast cells requires considerations of the underlying
experimental evidence. We consider mast cell functions here in
the context of innate immunity, allergy, adaptive immunity, auto-18 Immunity 37, July 27, 2012 ª2012 Elsevier Inc.immunity, and vascular diseases and in association with tumors,
knowing that this list is not exhaustive. We deem it useful to
operationally distinguish protective, harmful, and currently ill-
defined roles of mast cells (Figure 1). In the latter, we refer to
reports on mast cell functions that have either been shown in
the context of Kit deficiency only or that have not been confirmed
when tested in Kit-independent models (e.g., deviated Th2
response, antibody-driven arthritis, EAE, or the role of IL-10 in
contact hypersensitivity) (Dudeck et al., 2011; Feyerabend
et al., 2011; Katz and Austen, 2011; Knight et al., 2000) or in
cases of conflicting data between Kit mutants (e.g., in collagen-
induced arthritis (Zhou et al., 2007), EAE (Bennett et al., 2009;
Li et al., 2011; Piconese et al., 2011; Secor et al., 2000), or tumor
growth (Gounaris et al., 2007; Sinnamon et al., 2008).
Protective Roles of Mast Cells
Mast cells are able to degrade the snake venom toxin sarafotoxin
6b (S6b) (Metz et al., 2006), and the responsible enzyme for this
protective C-terminal cleavage is Cpa3 (Schneider et al., 2007).
Analysis of a panel of now available mouse mast cell protease
mutants revealed that mouse mast cell protease-4 (Mcpt4),
a chymase, can degrade helodermin, a toxic component of
Gila monster venom, and reduce the morbidity and mortality
induced by venoms from scorpion species (Akahoshi et al.,
2011). Although the underlying data on toxin degradation are
compelling, and such mechanisms of toxin inactivation may be
vital for mice in the wild, more or broader functions of mast cell
proteases in immunity may still be uncovered. It seems to
confound immunological wisdom of receptor diversity and
antigen recognition that mast cells use individual proteases to
degrade single or small groups of toxins.
Endothelin 1 (ET-1), the most potent blood pressure regulating
endogenous peptide, is highly homologous in peptide sequence
to S6b. ET-1 can activate mast cells by binding to endothelin
receptors (ET-A) on the surface of mast cells. In response,
mast cells degranulate and release mediators including IL-6
and TNF-a (Matsushima et al., 2004). Mast cell proteases
degrade ET-1, and studies using pharmacological inhibitors
initially concluded that a chymase was the responsible enzyme
(Maurer et al., 2004). However, mice expressing an inactive
form of Cpa3 with no other defects in mast cell proteases failed
to degrade ET-1, demonstrating that Cpa3, and not chymase
activity, is essential (Schneider et al., 2007). The physiological
role of endothelin degradation by mast cells remains enigmatic.
The test for mouse survival upon intraperitoneal injection of
ET-1 (Maurer et al., 2004; Schneider et al., 2007) is an artificial
system, and the physiological or pathological implications,
possibly involving the local regulation of blood pressure, of this
response loop (activation by and degradation of ET-1 by mast
cells) are elusive.
Mast cells have been reported to play important roles in resis-
tance to bacterial and parasitic infections which has been
comprehensively reviewed (Abraham and St John, 2010). In
addition to the CLP experiments referred to above (Echtenacher
et al., 1996), the role of mast cells in bacterial resistance has
originally been studied by subjecting KitW/Wvmice to intraperito-
neal injection of Klebsiella pneumonia (Malaviya et al., 1996). The
impaired clearance of this infection by Kit mutant mice sug-
gested that mast cells can promote survival during a bacterial
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Figure 1. Diversity and Experimental Basis of Assumed Functions of Mast Cell in the Immune System and Beyond
Mast cell functions are classified into ‘‘protective,’’ ‘‘harmful,’’ and ‘‘ill-defined.’’ The latter category comprises studies that were based on analyses ofKitmutants
only, that gave conflicting data in different Kit mutants, or that have not been confirmed when tested in Kit-independent models. These categories are further
structured for immunological functions, e.g., innate and adaptive immunity, allergy, or autoimmunity, and for diseases, e.g., infections, anaphylaxis, or arthritis.
The experimental bases of the mast cell analyses are discussed and referenced in the text.
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Perspectiveinfection by promoting neutrophil recruitment, and evidence
pointed at an important role of TNF-a in this process. These
findings have been substantiated independently of a Kit
mutant mouse by a report showing that Mcpt6/ mice cannot
efficiently clear Klebsiella pneumoniae from the peritoneal
cavity (Thakurdas et al., 2007).Mcpt6/mice also have pheno-
types different from wild-type mice in Trichinella (T.) spiralis
infection (Shin et al., 2008), in the K/BxN serum transfer arthritis
(Shin et al., 2009), in allograft tolerance (de Vries et al., 2010), in
experimental colitis (Hamilton et al., 2011), and in aortic aneu-
rysm formation (Zhang et al., 2011). It is intriguing that a single
tryptase seems to be directly or indirectly involved in the regu-
lation of such diverse pathologies. However, Mcpt6 mRNA
expression, though strongest in mast cells, is not absolutely
restricted to mast cells but expression is also found in subsets
of macrophages and dendritic cells, and in other tissues (www.
immgen.org). Hence, although the experiments listed above
invoke mast cells as the only source of Mcpt6, formal proof of
an involvement of mast cells in these models would require
deletion of Mcpt6 specifically in mast cells by conditional gene
targeting.
Immunity against parasites is among the most widely believed
mast cell functions. However, evidence from specific host-
pathogen interactions is limited. The expulsion of T. spiralis
was delayed in KitW/Wvmice (Ha et al., 1983). Compound KitW/Wv
IL-3/ mice displayed delayed expulsion of the nematode
Strongyloides venezuelensis but not of Nippostrongylus (N.)
brasiliensis (Lantz et al., 1998), suggesting roles for IL-3 or Kit
or mast cells in immunity against some parasites. More specifi-cally,Mcpt1 null mice showed a substantially delayed expulsion
of T. spiralis and increased deposition of muscle larvae.
However, inN. brasiliensis-infectedMcpt1/mice, worm expul-
sion was not impaired (Knight et al., 2000). Interestingly, a
comparison of T. spiralis infections in KitW/Wv and Mcpt1/
mice revealed comparably delayed parasite elimination and
ameliorated infection-associated enteropathy in both strains of
mice, while the Th2 responses were significantly reduced only
in KitW/Wv but not in Mcpt1/ mice (Lawrence et al., 2004).
This is another example of dissociated phenotypes comparing
Kit mutants and specific mast cell mutants. Finally, immunity
to N. brasiliensis and to H. polygyrus was unimpaired in mast
cell-deficient Cpa3Cre/+ mice (unpublished data). In conclusion,
the involvement of mast cells or their products in nematode
expulsion appears to be a selective process, and more work
will be required to understand the mechanisms underlying this
parasite specificity.
From the data summarized here, a picture emerges in which
mast cells may contribute to resistance against certain patho-
gens but one cannot assume that mast cells are broadly
involved in immunity against bacteria, viruses, and parasites.
More work will be required to understand the potential selec-
tivity of protective mast cell responses.
Harmful Roles of Mast Cells
Roles of mast cells in anaphylaxis have been documented
in several independent systems. Kit mutants are defective in
IgE-driven local and systemic anaphylaxis (Becker et al., 2011;
Finkelman, 2007; Martin et al., 1989; Zhou et al., 2007). SeveralImmunity 37, July 27, 2012 ª2012 Elsevier Inc. 19
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for susceptibility to passive IgE-mediated local and systemic
type I hypersensitivity (Feyerabend et al., 2011; Lilla et al.,
2011; Sawaguchi et al., 2012). Depending on the extent of mast
cell deficiency, anaphylaxis was abrogated or strongly amelio-
rated. A key pathophysiological parameter in anaphylaxis-asso-
ciated shock, the drop in body temperature, requires histamine
synthesis, which is ablated in mice deficient for histidine decar-
boxylase (Makabe-Kobayashi et al., 2002). Hence, there is now
definitive evidence for the essential role of mast cells in the initi-
ation of IgE-mediated allergic and anaphylactic reactions.
In mouse models of asthma, animals undergo repetitive
immunization and challenge with Ova, and airway hyperresist-
ance (AHR) is measured upon methacholine inhalation. Although
it is generally accepted that IL-4, which could be provided
by mast cells and basophils, is a central player in development
of AHR (Maes et al., 2012), the extent of mast cell contribution
in this model of mouse asthma seems to be highly dependent
on the immunization protocol (Williams and Galli, 2000) and on
the genetic background of the mice (Becker et al., 2011).
Combined studies on Mas-TRECK and Bas-TRECK mice
demonstrated the involvement of mast cells in the effector phase
of AHR (Sawaguchi et al., 2012).
Reports on the role of mast cells in contact hypersensitivity
(CSH) have been controversial (Biedermann et al., 2000; Grim-
baldeston et al., 2007; discussed in Dudeck et al., 2011),
perhaps partially because of different skin reactions that are
summarized as ‘‘CHS.’’ The classical assay is done by sensiti-
zation of mice with small haptens or irritants like DNFB, TNCB,
or oxazolone on the shaved trunk skin, followed by challenge
on the ear skin a few days later, leading to ear swelling and
inflammation. This response is regarded as a prototype of
T cell-mediated delayed type hypersensitivity (DTH). However,
several phases of ear swelling can be observed during the
whole time course, which probably depend on different mecha-
nisms and effector cell types. Dudeck et al. demonstrated
that DNFB or FITC cause ear swelling already within 2 hr and
that this response is mast cell dependent and sensitization inde-
pendent. Ear swelling 24–48 hr after challenge and migration of
DCs to the draining lymph nodes is also facilitated by mast cell
activation in CHS (Dudeck et al., 2011; Otsuka et al., 2011). Inter-
estingly, KitW-sh/W-sh and KitW/Wv mice, but not mast cell-defi-
cient mice wild-type for Kit, showed exaggerated and prolonged
CHS responses (ear swelling 4–6 days after challenge) (Dudeck
et al., 2011; Grimbaldeston et al., 2007). IL-10 production might
here be inhibitory but it is not mast cell-derived IL-10 in themodel
examined by Dudeck et al. (2011).
Mast cells have been associated with vascular diseases
and tissue remodeling in humans. Several mast cell protease
knockout mice have been used in different disease models. In
experimental abdominal aortic aneurysm, tryptase (Mcpt6) and
chymase (Mcpt4)-deficient mice, but not Mcpt5/ mice, had
significantly reduced inflammatory cell infiltrations and showed
less aortic expansion and lesions (Sun et al., 2009; Zhang
et al., 2011). Experiments on epidermal burn injury showed
that Mcpt4/ or Mcpt5/ mice, but not mice lacking Mcpt6
or Mcpt7 proteins or mice lacking Cpa3 activity, were protected
from scald injury. Topical application of the respective enzymes
restored susceptibility (Younan et al., 2010).20 Immunity 37, July 27, 2012 ª2012 Elsevier Inc.In sum, harmful roles of mast cells are among the best-charac-
terized consequences of mast cell activation.
Ambiguous Roles of Mast Cells
The conclusion that mast cells have a critical protective role in
resistance to enteromicrobial sepsis in the CLP model was
initially based on experiments in KitW/Wv mice (Echtenacher
et al., 1996). However, a recent study using KitW/Wv and
KitW-sh/W-sh revealed a more complicated picture: depending
on the mouse strain background, the nature of the mutation
resulting in a mast cell deficiency, and type and severity of
infection, mast cells can have no effect, promote survival, or
increase mortality (Piliponsky et al., 2010). To our knowledge,
the role of mast cells in survival of CLP has not been confirmed
in Kit-independent mast cell-deficient mice, or in knockout
mice specifically and only lacking mast cell products, and
hence it cannot be excluded that Kit defects contribute to the
variability of the various strains in CLP sepsis experiments.
Mast cells have also been linked to adaptive immunity,
tolerance, and graft rejection. A link between mast cells and
regulatory T (Treg) cells has been suggested. The Treg cell
frequency is reduced in lymphoid organs of KitW-sh/W-sh mice
(Piconese et al., 2011). It is currently unknown whether this
phenotype is due to the absence of mast cells or not. In a model
of tolerance induction toward allogeneic skin grafts, mediated
by allogeneic splenocyte transplantation plus anti-CD154
(CD40 ligand), Noelle et al. reported an essential role of mast
cells in Treg cell-dependent peripheral tolerance (Lu et al.,
2006). Allogeneic F1 C57BL/6 (B6) 3 BALB/c skin was
accepted in tolerized B6 recipients but rejected in tolerized
KitW-sh/W-sh mice. However, in this setting of transplantation
greater than 50% of KitW-sh/W-sh mice even rejected B6 skin,
albeit with delayed kinetics. This rejection seems surprising
given that KitW-sh/W-sh mice were considered to be on the
C57BL/6 background. Minor histocompatibility differences or
lack of tolerance to antigens lacking in KitW-sh/W-sh mice
may account for this phenomenon. Hence, either donor and
host were not syngeneic or mast cell- and melanocyte-bearing
tissues induce an immune response in mice lacking these cells
in the first place. It remains to be determined whether these
histoincompatibilities between donor tissues and KitW-sh/W-sh
hosts, or only the mast cell- deficiency of KitW-sh/W-sh mice,
contributed to the failure of the tolerogenization protocol in
KitW-sh/W-sh mice. In any case, the possibility of an important
mast cell role in the establishment of tolerance to allogeneic
grafts is intriguing, and future work using inbred strains lacking
mast cells may further illuminate this area.
On the basis of studies in Kitmutant mice, major contributions
of mast cells in autoimmune disease models EAE, arthritis, and
type 1 diabetes have been postulated. Considerations on the
role of mast cells in EAE and the K/BxN arthritis model have
been presented above. Regarding diabetes, there has been
a notion that introduction of KitW/Wv mutations into nonobese
diabetic (NOD) mice protected from type 1 diabetes develop-
ment (Hatfield et al., 2010, J. Immunol., abstract). A role for
mast cells in diet-induced obesity (DIO) and diabetes-associated
parameters has been analyzed in KitW-sh/W-sh mice and in mice
treated with pharmacological mast cell stabilizers. Absence of
mast cells, or inhibition of mast cell degranulation, both reduced
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et al., 2009), as well as prolonged disease-free survival in dia-
betes-prone rats (Geoffrey et al., 2006). Another study, however,
reported delayed onset of diabetes in NOD mice treated with
anti-FcεRI antibody that activated basophils and mast cells
(Hu¨bner et al., 2011; reviewed in Shi and Shi, 2012).
Finally, roles of mast cells have been described in the areas of
arteriosclerosis, angiogenesis, tissue repair, and tumor growth.
Mast cells are equipped with potent vasoactive molecules,
including Vegf and famous heparin that can regulate vascular
growth and permeability (Oschatz et al., 2011; reviewed in
Kunder et al., 2011). Moreover, mast cells could modulate local
and systemic blood flow via the aforementioned Cpa3-mediated
degradation of endothelin 1. The spectrum of mast cell products
that have the potential to regulate vascular functions and
frequent blood vessel association of mast cells suggest that
mast cells could participate in cardiovascular pathology. Exper-
iments addressing the possible contributions of mast cells to
aortic aneurysm have been stated above. Potential roles of
mast cells in arteriosclerosis have also been suggested (re-
viewed in Bot and Biessen, 2011). Indicators of arteriosclerosis,
including atherogenic lipid profile, vascular inflammation, and
plaque dimensions, were ameliorated in Ldlr/KitW-sh/W-sh
mice (Heikkila¨ et al., 2010; Sun et al., 2007), and the IgE-FcεRI
axis seems to contribute to atherogenesis (Wang et al., 2011).
However, the link between mast cells, diet-induced blood lipids,
and arteriosclerosis remains to be understood more closely.
Given that Kit is expressed in hepatocytes, and that Kit signaling
has been linked to liver and lipid metabolism (Magnol et al.,
2007), mutations in Kit may not be neutral in arteriosclerosis
experiments.
Within the immune system, the impact of mast cell-derived
products on blood vessels may be a key driving force in the
initiation, enhancement, or maintenance of acute and chronic
inflammation. However, in these and further interesting aspects
of mast cell biology, including angiogenesis, tissue remodeling,
wound healing (Gilfillan and Beaven, 2011), and promotion of
or protection from cancer by participation as element of tumor
stroma (Tlsty and Coussens, 2006), the decisive question is
whether or not mast cells are functionally involved. In other
words, although there is ample structural evidence that mast
cells bear and release a host of tissue-modifying substances,
we still know too little about the functional meaning of these
data. Neither the mere presence of mast cells nor of their prod-
ucts are proof of functional importance, leaving the question
unsolved as to whether mast cells are bystanders or culprits
under any particular condition. Collectively, it is evident from
this discussion and the complexity of the underlying experiments
that many roles of mast cells in the immune system and beyond
remain presently ambiguous.
Concluding Remarks
Mast cells remain fascinating cells, yet many facets of their
physiological role in the immune system still need to be deter-
mined and understood.Kitmutantmice have served for decades
as standard models to test in vivo mast cell functions. Because
Kit is critically involved in the development and function of
many stem and mature cells inside and outside of the immune
system, phenotypes unrelated to the mast cell deficiency of Kitmutants may contribute to the experimental outcome of experi-
ments targeted to reveal only mast cell functions. The reconstitu-
tion of Kit mutants with cultured mast cells has been thought to
reliably indicate whether an observed defect is due to the lack
of mast cells. Recently, the first Kit-independent mast cell-defi-
cient mice have been reported. In thesemice, some key data ob-
tained earlier in the Kit mutant mast cell reconstitution system
have not been confirmed. Of course, this does not discredit all
of the available mast cell literature but cautions that conclusions
based on Kit mutations may not in every case hold true when
tested independently. Comfortingly, experiments in Kit-indepen-
dent models have confirmed some mast cell functions, most of
all the essential role of mast cells in mediating allergic disease
and anaphylaxis. Beyond this expected finding, selectively
mast cell-deficient mice have a surprisingly normal immune
system. In these mice as well as in mutants with specific loss of
mast cell products, mast cells have been shown to play a role
in the context of asthma, contact hypersensitivity, infections
with selective bacterial and parasitic pathogens, degradation of
toxins and endothelin, graft rejection, burn injury, and some
vascular pathologies. In these experiments, mast cells either
contributed to protection (as in toxin degradation or bacterial
resistance) or were harmful (as in anaphylaxis or inflammatory
exaggeration of burn injuries). By contrast, widespread functions
of mast cells in innate and adaptive immunity, as well as in auto-
immunity, immune metabolic diseases, and in many other areas
(Figure 1), remain currently ambiguous. The newmousemutants,
and probably tools to come, shall provide a broader basis for
conclusive experiments that will separate pivotal from less
important functions of mast cells in immunity.ACKNOWLEDGMENTS
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